CombiGene AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 4.74 million. Net income was SEK 4.52 million compared to net loss of SEK 15.4 million a year ago. Basic earnings per share from continuing operations was SEK 0.23 compared to basic loss per share from continuing operations of SEK 0.85 a year ago. Diluted earnings per share from continuing operations was SEK 0.23 compared to diluted loss per share from continuing operations of SEK 0.85 a year ago.
For the six months, sales was SEK 16.14 million. Net income was SEK 1.83 million compared to net loss of SEK 26.26 million a year ago. Basic earnings per share from continuing operations was SEK 0.09 compared to basic loss per share from continuing operations of SEK 1.78 a year ago. Diluted earnings per share from continuing operations was SEK 0.09 compared to diluted loss per share from continuing operations of SEK 1.78 a year ago.